Prognostic Significance of Programmed Cell Death 1 (PD-1) or PD-1 Ligand 1 (PD-L1) Expression in Epithelial-Originated Cancer
Open Access
- 1 February 2015
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Medicine
- Vol. 94 (6), e515
- https://doi.org/10.1097/md.0000000000000515
Abstract
The expression of programmed cell death 1 (PD-1) and its ligand (PD-L1) has been observed in various epithelial-originated malignancies. However, whether the expression of PD-L1 on tumor cells or the expression of PD-1 on tumor-infiltrating lymphocytes (TILs) is associated with patients’ survival remains controversial. Electronic databases were searched for eligible literatures. Data of hazard ratio (HR) for overall survival (OS) with 95% confidence interval (CI) according to the expression status of PD-L1 or PD-1 evaluated by immunohistochemistry were extracted. The outcomes were synthesized based on random-effects model. Subgroup analyses were proposed. Twenty-nine studies covering 12 types of epithelial-originated malignancies involving 7319 patients (2030/3641 cases for PD-L1 positive/negative, 505/1143 cases for PD-1 positive/negative) with available data of the outcome stratified by PD-L1/PD-1 status were enrolled. Epithelial-originated cancer patients with positive expression of PD-L1 on tumor tissues were associated with significantly poorer OS when compared to those with negative expression of PD-L1 (HR 1.81, 95% CI 1.33–2.46, P < 0.001). Similarly, patients with PD-1 positive expression on TILs had significantly shorter OS than the PD-1 negative group (HR 2.53, 95% CI 1.22–5.21, P = 0.012). In analyses of PD-L1, all subgroups showed consistent trends toward unfavorable prognoses of patients with positive PD-L1 expression, regardless of antibodies and evaluation cutoffs. Subgroup analyses on PD-1 were not available due to limited data. PD-L1 or PD-1 expression status is a significant prognostic factor in epithelial-originated malignancies.Keywords
This publication has 40 references indexed in Scilit:
- B7-H1 Expression Is Associated with Poor Prognosis in Colorectal Carcinoma and Regulates the Proliferation and Invasion of HCT116 Colorectal Cancer CellsPLOS ONE, 2013
- Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapyExpert Opinion on Biological Therapy, 2013
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunityCurrent Opinion in Immunology, 2012
- Clinical Significance of the Costimulatory Molecule B7-H1 in Barrett CarcinomaThe Annals of Thoracic Surgery, 2011
- Expression of B7-H1 protein in human pancreatic carcinoma tissues and its clinical significanceChinese Journal of Cancer, 2009
- Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical CarcinomaClinical Cancer Research, 2009
- Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular CarcinomaClinical Cancer Research, 2009
- Practical methods for incorporating summary time-to-event data into meta-analysisTrials, 2007
- Checkpoint Blockade in Cancer ImmunotherapyAdvances in Immunology, 2006
- Costimulatory molecule B7‐H1 in primary and metastatic clear cell renal cell carcinomaCancer, 2005